Patrys Limited · ASX:PAB
Patrys — Investor Presentation (November 2012)
29 slides from Patrys's investor presentation, Nov 27, 2012
Slide 1: Investor Presentation
For personal use only Investor Presentation Dr. Marie Roskrow, CEO & Managing Director November 2012 ASX: PAB
Slide 2: Safe Harbour Statement
Safe Harbour Statement For personal use only The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of los
Slide 3: Why Invest in Patrys Now?
Why Invest in Patrys Now? For personal use only Patrys is an ASX-listed clinical-stage company focussing on the discovery and development of natural human antibodies for the treatment of cancer Unique antibody discovery platform producing Abs ripe for clinical development Exciting Antibody Stron
Slide 4: Corporate Overview
Corporate Overview For personal use only KEY STATISTICS – 20 NOVEMBER 2012 (AUD$) 2012 SHARE PERFORMANCE ASX Code PAB Current share price $0.037 Share Price A$ 52 Week High $0.047 52 Week Low $0.015 Shares on Issue 507,362,177 Market Capitalisation $18.8 m Average Daily Volume ~325,000 Shareholders
Slide 5: FY12 Capital Raisings
FY12 Capital Raisings For personal use only 2 December 2011 22 June 2012 Amount: $3.4m Amount: $2.8m Issue Price: 3 cents per share Issue Price: 2 cents per share Share Placement Method: Share Placement Method: & SPP Current cash position (Sept. 2012): $7m Runway to early 2014 5
Slide 6: Patrys' Antibody Platform
Patrys’ Antibody Platform For personal use only Spleen / lymph nodes Proprietary antibody isolated from multiple capture technology patients 40,000 MAbs Captured 27% IgG IgM » clear choice of immune system 61% 12% IgM for fighting cancer IgA 0.10% IgG 14 products 99.90% evaluated to IgM Screening Te
Slide 7: Unique features of the Patrys Antibodies
Unique features of the Patrys Antibodies Produces IgM antibodies: For personal use only Body’s 1st line of defence as part of innate immune response Large structures capable of binding & killing several tumour cells at the same time Each antibody produced binds a unique cancer-specific targe
Slide 8: Pipeline
Pipeline For personal use only Product Discovery Preclinical Phase I Phase 2a PAT-SM6 Phase I Completed Melanoma PAT-SM6 Multiple Myeloma Phase I/IIa Commenced 4Q2012 PAT-LM1 Solid Tumours Phase I/IIa PAT-SC1 Gastric Cancer Completed Out- Licensing Candidate PAT-SM1 SM4 SM5 NM3 8
Slide 9: Patrys Lead Antibody - PAT-SM6
Patrys Lead Antibody - PAT-SM6 PAT-SM6: For personal use only IgM isotype, λ-light chain Isolated from stomach cancer patient Recombinantly expressed in PER.C6® Targets tumour specific epitope on GRP78 Binds also to oxidised LDL and VLDL Mode of Action: Internalisation upon binding of ox
Slide 10: PAT-SM6 Melanoma Phase I Trial
PAT-SM6 Melanoma Phase I Trial For personal use only 9 Patients enrolled at Royal Adelaide Hospital and Princess Alexandra Hospital, Brisbane: October 2010 – February 2012 Primary endpoint: No adverse events recorded in any patient Secondary endpoints: Half-life of 5.7 hours reported (pharmaco
Slide 11: PAT-SM6 Melanoma Trial IHC/Apoptosis
PAT-SM6 Melanoma Trial IHC/Apoptosis Pre-treatment biopsy Post-treatment biopsy For personal use only Patient 1 Patient 2 Tumour biopsies were collected pre and post treatment with PAT-SM6, fixed in formalin and embedded in paraffin. An antibody specific for PAT-SM6 (PAT-SM6 anti Idiotype antibody)
Slide 12: Multiple Myeloma - Opportunity
Multiple Myeloma - Opportunity A cancer of the plasma cells in bone marrow. These cells grow out of control and form For personal use only tumours in solid bone, cause damage to other organs Estimated to be more than 220,000 cases worldwide and incidence increasing 5 year survival of 29%. Desp
Slide 13: Multiple Myeloma - Pathology
Multiple Myeloma - Pathology For personal use only Abnormal plasma cells (myeloma Monoclonal gammopathy detected by cells) secrete lots of “useless” electrophoresis antibodies (M proteins) Myeloma cells crowd out other blood cells resulting in anaemia, thrombocytopenia (bleeding) and leucopeni
Slide 14: Multiple Myeloma - Presentation
Multiple Myeloma - Presentation For personal use only Bone disease and hypercalcaemia 14
Slide 15: Multiple Myeloma - Presentation
Multiple Myeloma - Presentation For personal use only Evidence of bone marrow failure 15
Slide 16: Therapies for Multiple Myeloma
Therapies for Multiple Myeloma For personal use only Proteosome inhibitors Clinical studies Bortezomib (Velcade) Small molecules Carfilzomib (Kyprolis) Antibodies, peptides IMIDs Lanalidomid (Revlimid) Thalidomide Chemotherapeutics Melphalan Cisplatin Cyclophosphamide Dox
Slide 17: Antibodies in Clinical Trials for MM
Antibodies in Clinical Trials for MM For personal use only Daratumumab PAT-SM6 Elotuzumab GRP78 BHQ880 CD138 toxin- conjugated Antibodies in all stages of clinical development 17
Slide 18: Preclinical Data I – Multiple Myeloma
Preclinical Data I – Multiple Myeloma For personal use only Patient tissue sourced Isotype Control CD138 PAT-SM6 from 11 patients at primary diagnosis, 9 with MM1 relapsed disease and 4 healthy controls IHC staining on bone marrow sections show MM2 binding of PAT-SM6 in 20/20 MM patients (primar
Slide 19: Phase I/IIa PAT-SM6 Multiple Myeloma
Phase I/IIa PAT-SM6 Multiple Myeloma Study Design For personal use only Screening Day -14 to -1 Treatment Day 1, 3, 8, 10 with PAT-SM6 Ambulatory visits on Day 15 and 22 After completion of Day 15: DSMB decision on dose escalation Serological staging Day 29 Day 36 ≥ PR* ≥ PR* SD or PD Treatment Trea
Slide 20: Projected Clinical Trial Timelines
Projected Clinical Trial Timelines For personal use only First patient enrolled Nov. 7th, 2012 Data from 1st cohort expected 1Q2013 Full recruitment expected within 12 months Data to be released on a “rolling” basis 20
Slide 21: Future Options for PAT-SM6
Future Options for PAT-SM6 For personal use only Positive Phase I/IIa MM clinical trial data + existing positive Phase I melanoma data + extensive preclinical package: Option 1: Do a deal Genmab / J&J Jansson Biotech Daratumumab (anti-CD38): Phase I/IIa Total deal worth up to $1.135B announced
Slide 22: Plans for 2013
Plans for 2013 For personal use only Execute PAT-SM6 Phase I/IIa open-label multi-dose multiple myeloma clinical trial Continue preclinical work with PAT-SM6 and multiple myeloma (animal models, drug combination studies) Expand external collaborations around all programmes to generate new data
Slide 23: For Further Information
For Further Information For personal use only Contact Details: Dr. Marie Roskrow, Chief Executive Officer Mr. Roger McPherson, Chief Financial Officer Ph: +61 3 9670 3273 Email: info@patrys.com Website: www.patrys.com 23
Slide 24: Appendix
For personal use only Appendix 24
Slide 25: PAT-LM1 Antibody & Target
PAT-LM1 Antibody & Target For personal use only PAT-LM1: IgM isotype, λ-light chain Isolated from a lung cancer patient Recombinantly expressed in PER.C6® Targets tumour-specific epitope of surface-expressed NONO (non-POU-domain-containing octomer binding protein) Mode of Action: NONO main
Slide 26: PAT-LM1 Preclinical Data
PAT-LM1 Preclinical Data + control - control PAT-LM1 0.4 For personal use only Lung Squamous without C1q coating Cell Carcinoma 0.35 with 5μ/ml C1q coating 0.3 Colon 0.25 Adenocarcinoma 0.2 OD655 0.15 Esophagus Squamous Cell Carcinoma 0.1 0.05 Breast Ductal Adenocarcinoma 0 20μg 10μg 5μg 1μg 0.5μg L
Slide 27: PAT-SC1 (Gastric Cancer)
PAT-SC1 (Gastric Cancer) For personal use only Pentameric IgM antibody Overview First Patrys Ab evaluated in clinical trial Target: Binds to isoform of CD55 (Decay Accelerating Factor) expressed on CD55 surface of multiple types of cancer cells Phase I/IIa open-label trial conducted 1997-200
Slide 28: PAT-SC1 Human Trial - Overview
PAT-SC1 Human Trial - Overview For personal use only Open-label, randomised investigator lead Phase I/II study between 1997 and 2001 conducted at the University of Würzburg, Germany using PAT-SC1 Stomach hybridoma material Cancer CD55SC-1 positive patients given 20 mg PAT-SC1 i.v. of PAT-SC1 ove
Slide 29: PAT-SC1 Human Trial – Survival Data
PAT-SC1 Human Trial – Survival Data For personal use only 10-Year Survival Data Survival of treated patients (Group 3; CD55 positive and PAT-SC1 treated) patients followed over time and compared to historic control patients (Group 1; CD55 positive) with R0 stage gastric cancer who did not receive